Morningstar

Hengrui Pharma Signs Milestone Drug-Development Deal With GSK

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
Fierce Biotech

GSK walks away from $100M bet on Mersana's STING ADC, pauses mRNA bird flu shot program

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an ...
MarketWatch

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

The MarketWatch News Department was not involved in the creation of this content. -- Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for ...
Seeking Alpha

IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK

Selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK Observed complete responses in preclinical combination studies of Pol Theta Helicase DC with ...
Morningstar

Helix Announces Multi-Year Strategic Collaboration with GSK to Drive Precision Medicine Development

SAN MATEO, Calif., Jan. 7, 2026 /PRNewswire/ -- Helix, the leading enterprise genomics company, today announced a multi-year strategic collaboration with GSK, the global biopharma company. This ...